Free tool
Drug literature search
Last checked: Nov 20, 2026Source: PubMed, Europe PMC, OpenAlex
312 results in PubMed
Peer-reviewed biomedical literature from the US National Library of Medicine, most relevant first. Showing the first 25. Limited to clinical trials, meta-analyses and systematic reviews.
- Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis.
Wong WL, Su X, Li X, et al. · Lancet Glob Health · 2014Meta-Analysis, Research Support, Non-U.S. Gov't
- LIGHTSITE III: 13-Month Efficacy and Safety Evaluation of Multiwavelength Photobiomodulation in Nonexudative (Dry) Age-Related Macular Degeneration Using the Lumithera Valeda Light Delivery System.
Boyer D, Hu A, Warrow D, et al. · Retina · 2024Randomized Controlled Trial
- Subretinal Photovoltaic Implant to Restore Vision in Geographic Atrophy Due to AMD.
Holz FG, Le Mer Y, Muqit MMK, et al. · N Engl J Med · 2026Multicenter Study, Clinical Trial
- Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials.
Heier JS, Lad EM, Holz FG, et al. · Lancet · 2023Randomized Controlled Trial, Clinical Trial, Phase III
- Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration.
Evans JR, Lawrenson JG · Cochrane Database Syst Rev · 2023Systematic Review, Research Support, Non-U.S. Gov't
- OCT Prognostic Biomarkers for Progression to Late Age-related Macular Degeneration: A Systematic Review and Meta-analysis.
Trinh M, Cheung R, Duong A, et al. · Ophthalmol Retina · 2024Systematic Review, Meta-Analysis
- Oral Antioxidant and Lutein/Zeaxanthin Supplements Slow Geographic Atrophy Progression to the Fovea in Age-Related Macular Degeneration.
Keenan TDL, Agrón E, Keane PA, et al. · Ophthalmology · 2025Randomized Controlled Trial, Multicenter Study
- C5 Inhibitor Avacincaptad Pegol for Geographic Atrophy Due to Age-Related Macular Degeneration: A Randomized Pivotal Phase 2/3 Trial.
Jaffe GJ, Westby K, Csaky KG, et al. · Ophthalmology · 2021Clinical Trial, Phase II, Clinical Trial, Phase III
- A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8.
Arch Ophthalmol · 2001Clinical Trial, Comparative Study
- LONG-TERM EFFICACY AND SAFETY OF PHOTOBIOMODULATION IN DRY AGE-RELATED MACULAR DEGENERATION (LIGHTSITE III: 24-MONTH ANALYSIS).
Jaffe GJ, Boyer D, Hu A, et al. · Retina · 2026Randomized Controlled Trial, Research Support, N.I.H., Extramural
- Targeting C3b/C4b and VEGF with a bispecific fusion protein optimized for neovascular age-related macular degeneration therapy.
Yang S, Li T, Jia H, et al. · Sci Transl Med · 2022Clinical Trial, Research Support, Non-U.S. Gov't
- AGE-RELATED MACULAR DEGENERATION.
Gheorghe A, Mahdi L, Musat O · Rom J Ophthalmol · 2015Systematic Review
- Avacincaptad pegol for geographic atrophy secondary to age-related macular degeneration: 18-month findings from the GATHER1 trial.
Patel SS, Lally DR, Hsu J, et al. · Eye (Lond) · 2023Randomized Controlled Trial, Clinical Trial, Phase II
- A DOUBLE-MASKED, RANDOMIZED, SHAM-CONTROLLED, SINGLE-CENTER STUDY WITH PHOTOBIOMODULATION FOR THE TREATMENT OF DRY AGE-RELATED MACULAR DEGENERATION.
Markowitz SN, Devenyi RG, Munk MR, et al. · Retina · 2020Randomized Controlled Trial
- The effect of complement C3 or C5 inhibition on geographic atrophy secondary to age-related macular degeneration: A living systematic review and meta-analysis.
Garg A, Nanji K, Tai F, et al. · Surv Ophthalmol · 2024Meta-Analysis, Research Support, Non-U.S. Gov't
- Vision Loss Reduction with Avacincaptad Pegol for Geographic Atrophy: A 12-Month Post Hoc Analysis of the GATHER1 and GATHER2 Trials.
Danzig CJ, Khanani AM, Kaiser PK, et al. · Ophthalmol Retina · 2024Randomized Controlled Trial, Clinical Trial, Phase III
- Progression of Geographic Atrophy in Age-related Macular Degeneration: AREDS2 Report Number 16.
Keenan TD, Agrón E, Domalpally A, et al. · Ophthalmology · 2018Clinical Trial, Phase III, Multicenter Study
- Complement C3 Inhibitor Pegcetacoplan for Geographic Atrophy Secondary to Age-Related Macular Degeneration: A Randomized Phase 2 Trial.
Liao DS, Grossi FV, El Mehdi D, et al. · Ophthalmology · 2020Clinical Trial, Phase II, Multicenter Study
- Efficacy and safety of complement inhibitors in patients with geographic atrophy associated with age-related macular degeneration: a network meta-analysis of randomized controlled trials.
Wang H, Zheng J, Zhang Q, et al. · Front Pharmacol · 2024Systematic Review
- Outer Retinal Tubulation in Geographic Atrophy.
Hatcher KA, Shah BK, Burch M, et al. · Ophthalmic Surg Lasers Imaging Retina · 2024Randomized Controlled Trial, Clinical Trial, Phase II
- Survival of an HLA-mismatched, bioengineered RPE implant in dry age-related macular degeneration.
Kashani AH, Lebkowski JS, Hinton DR, et al. · Stem Cell Reports · 2022Clinical Trial, Phase I, Clinical Trial, Phase II
- Disease Activity and Therapeutic Response to Pegcetacoplan for Geographic Atrophy Identified by Deep Learning-Based Analysis of OCT.
Schmidt-Erfurth U, Mai J, Reiter GS, et al. · Ophthalmology · 2025Randomized Controlled Trial, Clinical Trial, Phase III
- Pegcetacoplan Treatment for Geographic Atrophy in Age-Related Macular Degeneration Over 36 Months: Data From OAKS, DERBY, and GALE.
Wykoff CC, Holz FG, Chiang A, et al. · Am J Ophthalmol · 2025Clinical Trial, Phase III, Multicenter Study
- Simultaneous perception of prosthetic and natural vision in AMD patients.
Palanker D, Le Mer Y, Mohand-Said S, et al. · Nat Commun · 2022Clinical Trial, Research Support, N.I.H., Extramural
- Safety and tolerability of RPESC-RPE transplantation in patients with dry age-related macular degeneration: Low-dose clinical outcomes.
Rao RC, Arduini BL, Borden S, et al. · Cell Stem Cell · 2025Clinical Trial, Phase I, Clinical Trial, Phase II
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.